Eine Studie zur Bewertung der Langzeitsicherheit von Inclacumab, das Teilnehmern mit Sichelzellenanämie verabreicht wird
Eine Open-Label-Verlängerungsstudie zur Bewertung der Langzeitsicherheit von Inclacumab, verabreicht an Teilnehmer mit Sichelzellenanämie, die an einer klinischen Studie mit Inclacumab teilgenommen haben
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.
All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Rio de Janeiro, Brasilien, 20211-030
- Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
-
São Paulo, Brasilien, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, Brasilien, 01232-010
- Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
-
São Paulo, Brasilien, 08270-120
- CEPEC-Centro de Pesquisa Clinica
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41253-190
- Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
-
-
Pernambuco
-
Recife, Pernambuco, Brasilien, 50070-460
- Multihemo Servicos Medicos S/A
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasilien, 14051-140
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São José do Rio Preto, São Paulo, Brasilien, 15090-000
- Fundação Faculdade Regional de Medicina de São José do Rio Preto
-
-
-
-
-
Eldoret, Kenia, 30100
- International Cancer Institute
-
Nairobi, Kenia, 00100
- Gertrude's Children's Hospital
-
Nairobi, Kenia, 00100
- Kenya Medical Research Institute - Centre for Respiratory Disease Research
-
Nairobi, Kenia, 00200
- Strathmore University CREATES
-
-
Siaya County
-
Kisumu, Siaya County, Kenia, 40600
- KEMRI/CRDR Siaya Clinical Research Annex
-
-
-
-
Atlántico
-
Barranquilla, Atlántico, Kolumbien, 080020
- Clinica de la Costa Ltda.
-
-
Cesar Department
-
Valledupar, Cesar Department, Kolumbien, 200001
- Sociedad de Oncología y hematología del Cesar
-
-
-
-
Beirut
-
Hamra, Beirut, Libanon
- American University of Beirut Medical Center
-
-
North Lebanon
-
Tripoli, North Lebanon, Libanon
- Nini Hospital
-
-
-
-
-
Enugu, Nigeria, 460000
- University of Nigeria Teaching Hospital
-
Kaduna, Nigeria, 800212
- Barau Dikko Teaching Hospital/Kaduna State University
-
Kano, Nigeria, 700223
- Aminu Kano Teaching Hospital
-
Lagos, Nigeria, 100254
- Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
-
-
Cross River State
-
Calabar, Cross River State, Nigeria, 540242
- University of Calabar Teaching Hospital
-
-
Federal Capital Territory
-
Abuja, Federal Capital Territory, Nigeria, 900211
- National Hospital Abuja
-
Gwagwalada, Federal Capital Territory, Nigeria, 902101
- University of Abuja Teaching Hospital
-
-
Kaduna State
-
Zaria, Kaduna State, Nigeria, 810105
- Ahmadu Bello University Teaching Hospital
-
-
-
-
-
Muscat, Oman, 123
- Sultan Qaboos University Hospital
-
-
-
-
Southern
-
Jizan, Southern, Saudi-Arabien, 82943
- Prince Mohammed bin Nasser Hospital
-
-
-
-
-
Dar es Salaam, Tansania, 11101
- National Institute for Medical Research (NIMR)
-
-
-
-
-
Adana, Türkei (türkiye), 01130
- Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
-
Adana, Türkei (türkiye), 01250
- Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
-
Ankara, Türkei (türkiye), 06430
- Hacettepe University Ihsan Dogramaci Children Hospital
-
-
-
-
Alabama
-
Mobile, Alabama, Vereinigte Staaten, 36604
- University of South Alabama Children's and Women's Hospital
-
Mobile, Alabama, Vereinigte Staaten, 36604
- Strada Patient Care Center, Pediatric Hematology
-
Mobile, Alabama, Vereinigte Staaten, 36606
- South Alabama Medical Science Foundation
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72202
- Arkansas Children's Hospital
-
-
California
-
Orange, California, Vereinigte Staaten, 92868
- UC Irvine Medical Center
-
-
Connecticut
-
Farmington, Connecticut, Vereinigte Staaten, 06030
- UConn-Neag Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois Hospital and Health Sciences System (UI Health)
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois at Chicago (UIC) Clinical Research Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute IDS Pharmacy
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham And Woman's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Hospitals - Michigan Medicine
-
-
New York
-
The Bronx, New York, Vereinigte Staaten, 10461
- Jacobi Medical Center
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Duke University Medical Center
-
Durham, North Carolina, Vereinigte Staaten, 27710
- DUMC Investigational Drug Services Pharmacy
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- McGovern Medical School at UTHealth
-
Houston, Texas, Vereinigte Staaten, 77030
- UT Physicians Comprehensive Sickle Cell Center Houston
-
Houston, Texas, Vereinigte Staaten, 77030
- UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Participants who meet all the following criteria will be eligible for study enrollment:
-
Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
-
Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
-
Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.
-
If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
-
Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:
- Female participant who is breastfeeding or pregnant.
- Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
- Participant withdrew consent from the originating inclacumab clinical study.
- Participant was lost to follow-up from the originating inclacumab clinical study.
- Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Inclacumab 30 mg/kg
Inclacumab 30 mg/kg administered intravenously (IV) |
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs. |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Annualized Rate of Vaso-occlusive Crises (VOCs)
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Number of Inpatient Hospitalization Days for a VOC
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of SCD-related Urgent Care Visits
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Zeitfenster: From first dose of study treatment (Day 1) up to Week 48
|
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure. |
From first dose of study treatment (Day 1) up to Week 48
|
|
Annualized Rate of Complicated VOCs
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of Red Blood Cell (RBC) Transfusions
Zeitfenster: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Pfizer CT.gov Call Center, Pfizer
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- GBT2104-133
- 2020-005289-32 (EudraCT-Nummer)
- C5361003 (Andere Kennung: Alias Study Number)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .